Broken Antioxidant Switch Found in Autism Cells Points to New Treatment Target

Autism Spectrum Disorder (ASD) affects roughly 1 in 100 children worldwide and is increasingly linked to systemic oxidative stress and immune dysregulation, not just neural circuit abnormalities. A central unanswered question has been why antioxidant defenses appear functionally impaired in ASD despite evidence of pathway activation. This study directly addresses that paradox.

Researchers isolated primary dermal fibroblasts from five clinically diagnosed ASD patients (ages 7–29) and four age- and sex-matched neurotypical controls. Fibroblasts are an established and ethically accessible model for systemic redox biology. Using Western blotting, immunofluorescence, nuclear/cytoplasmic fractionation, and real-time RT-PCR, the team characterized the Nrf2-Keap1-BACH1 signaling axis under basal conditions and after pharmacological challenge.

The key finding was a striking dissociation between Nrf2 nuclear presence and its functional output. ASD fibroblasts showed constitutively elevated nuclear Nrf2, yet paradoxically expressed significantly less HO1 (heme oxygenase-1) mRNA and protein than controls. The explanation emerged from two concurrent defects: first, ASD cells had markedly elevated levels of BACH1 in the nucleus, where this transcriptional repressor outcompetes Nrf2 at antioxidant response element (ARE) sequences, effectively silencing HO1 and other cytoprotective genes. Second, ASD fibroblasts displayed elevated Keap1—the cytoplasmic anchor and E3-ligase adaptor that targets Nrf2 for proteasomal degradation—which prevented further Nrf2 nuclear translocation in response to sulforaphane (SFN), a well-characterized Nrf2 activator. SFN treatment that robustly increased nuclear Nrf2 in control cells produced no such response in ASD cells.

To test whether BACH1 was the functional bottleneck, the researchers treated ASD fibroblasts with hemin, a compound known to bind BACH1 directly, triggering its nuclear export and proteasomal degradation. Hemin treatment successfully restored HO1 gene and protein expression in ASD cells to levels comparable to controls. Critically, this rescue also translated to measurable mitochondrial improvement: mitochondrial ROS (mtROS) levels decreased and mitochondrial membrane potential was restored in ASD fibroblasts following hemin treatment, linking the BACH1-HO1 axis directly to mitochondrial dysfunction previously documented in this patient population.

These results build on the authors' prior work demonstrating NLRP3 inflammasome activation and mitochondrial dysfunction in ASD fibroblasts, now adding a molecular explanation for why the Nrf2 pathway fails to mount an effective antioxidant counter-response. The study positions BACH1 nuclear accumulation as a critical node in ASD redox pathophysiology and raises the possibility that pharmacological BACH1 inhibition—or hemin-like interventions—could correct the oxinflammatory imbalance underlying the disorder. However, the small cohort, fibroblast-only model, and lack of in vivo validation are important limitations requiring follow-up.